Overview

Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Efficacy and safety of 5-Azacytidin in the treatment of the haematological relapse in patients suffering from acute myeloid leukaemia or myelodysplastic syndrome with falling CD34-chimerism after hematopoietic stem cell transplantation.
Phase:
Phase 3
Details
Lead Sponsor:
Technische Universität Dresden